Curriculum Vitaes
Profile Information
- Affiliation
- Professor, Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University(Concurrent)Vice Director, International Center for Brain Science (ICBS)(Concurrent)Professor, Department of Behavioral Neuropharmacology, Graduate School of Medicine(Concurrent)Vice Director, Open Facility Center
- Degree
- M.S.(Meijo University)Ph.D.(Nagoya University)
- J-GLOBAL ID
- 200901083965882198
- researchmap Member ID
- 5000081871
Research Interests
7Research Areas
1Research History
5-
Jan, 2020 - Present
-
Jan, 2010 - Dec, 2019
-
Apr, 2006 - Dec, 2009
Committee Memberships
14-
Sep, 2021 - Present
-
Mar, 2019 - Present
-
Oct, 2016 - Present
-
Oct, 2016 - Present
-
Apr, 2013 - Dec, 2019
Awards
10-
Sep, 2017
-
Oct, 2015
-
Jul, 2013
-
Oct, 2012
Papers
187-
European Journal of Pharmacology, Jan, 2026
-
International Journal of Molecular Sciences, May 28, 2025
-
British Journal of Pharmacology, Dec 10, 2024Background and Purpose Alterations in tryptophan‐kynurenine (TRP‐KYN) pathway are implicated in major depressive disorder (MDD). α7 nicotinic acetylcholine (α7nACh) receptor regulates the hypothalamic–pituitary–adrenal (HPA) axis. We have shown that deficiency of kynurenine 3‐monooxygenase (KMO) induces depression‐like behaviour via kynurenic acid (KYNA; α7nACh antagonist). In this study, we investigated the involvement of the TRP‐KYN pathway in stress‐induced behavioural changes and the regulation of the HPA axis. Experimental Approach Mice were exposed to chronic unpredictable mild stress (CUMS) and subjected to behavioural tests. We measured TRP‐KYN metabolites and the expression of their enzymes in the hippocampus. KMO heterozygous mice were used to investigate stress vulnerability. We also evaluated the effect of nicotine (s.c.) on CUMS‐induced behavioural changes and an increase in serum corticosterone (CORT) concentration. Key Results CUMS decreased social interaction time but increased immobility time under tail suspension associated with increased serum corticosterone concentration. CUMS increased KYNA levels via KMO suppression with microglial decline in the hippocampus. Kmo+/− mice were vulnerable to stress: they exhibited social impairment and increased serum corticosterone concentration even after short‐term CUMS. Nicotine attenuated CUMS‐induced behavioural changes and increased serum corticosterone concentration by inhibiting the increase in corticotropin‐releasing hormone. Methyllycaconitine (α7nACh antagonist) inhibited the attenuating effect of nicotine. Conclusions and Implications CUMS‐induced behavioural changes and the HPA axis dysregulation could be induced by the increased levels of KYNA via KMO suppression. KYNA plays an important role in the pathophysiology of MDD as an α7nACh antagonist. Therefore, α7nACh receptor is an attractive therapeutic target for MDD.
-
Neuropsychopharmacology, Oct 11, 2024Abstract Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, social deficits, and cognitive impairments. Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of ASD in offspring. The prevailing pathophysiological hypothesis for ASD involves excitation/inhibition (E/I) imbalances and serotonergic dysfunction. Here, we investigated the association between glutamatergic-serotonergic neuronal interactions and ASD-like behaviors in mice exposed to prenatal VPA. Prenatal VPA exposure induced excessive repetitive self-grooming behavior and impaired social behavior and object recognition memory in young adult period. Prenatal VPA mice showed hyper-glutamatergic function (increase in basal extracellular glutamate levels and CaMKII phosphorylation) and hypo-serotonergic function (decrease in 5-hydroxyindoleacetic acid and stimulation-induced serotonin [5-HT] release, but an increase in 5-HT transporter expression) in the prefrontal cortex. Treatment with a low-affinity NMDA receptor antagonist (memantine), a selective 5-HT reuptake inhibitor (fluoxetine), and a 5-HT1A receptor agonist (tandospirone) attenuated both the increase in CaMKII phosphorylation and ASD-like behavior of prenatal VPA mice. Opto-genetic activation of the serotonergic neuronal system attenuated impairments in social behavior and object recognition memory in prenatal VPA mice. WAY-100635—a 5-HT1A receptor antagonist—antagonized the effect of fluoxetine on impaired social behavior and object recognition memory. These results suggest that E/I imbalance and ASD-like behavior are associated with hypo-serotonergic receptor signaling through 5-HT1A receptors in prenatal VPA mice.
-
Science signaling, 17(853) eado9852, Sep 10, 2024Structural plasticity of dendritic spines in the nucleus accumbens (NAc) is crucial for learning from aversive experiences. Activation of NMDA receptors (NMDARs) stimulates Ca2+-dependent signaling that leads to changes in the actin cytoskeleton, mediated by the Rho family of GTPases, resulting in postsynaptic remodeling essential for learning. We investigated how phosphorylation events downstream of NMDAR activation drive the changes in synaptic morphology that underlie aversive learning. Large-scale phosphoproteomic analyses of protein kinase targets in mouse striatal/accumbal slices revealed that NMDAR activation resulted in the phosphorylation of 194 proteins, including RhoA regulators such as ARHGEF2 and ARHGAP21. Phosphorylation of ARHGEF2 by the Ca2+-dependent protein kinase CaMKII enhanced its RhoGEF activity, thereby activating RhoA and its downstream effector Rho-associated kinase (ROCK/Rho-kinase). Further phosphoproteomic analysis identified 221 ROCK targets, including the postsynaptic scaffolding protein SHANK3, which is crucial for its interaction with NMDARs and other postsynaptic scaffolding proteins. ROCK-mediated phosphorylation of SHANK3 in the NAc was essential for spine growth and aversive learning. These findings demonstrate that NMDAR activation initiates a phosphorylation cascade crucial for learning and memory.
Misc.
242-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 106 231P-231P, 2008
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 106 233P-233P, 2008
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 106 138P-138P, 2008
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 106 181P-181P, 2008
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 106 55P-55P, 2008
-
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 128 69-69, 2008
-
NEUROSCIENCE RESEARCH, 61 S129-S129, 2008
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 106 174P-174P, 2008
-
J. Pharmacol. Sci., 108 408-414, 2008 Peer-reviewedInvited
-
JOURNAL OF NEUROCHEMISTRY, 103(6) 2589-2596, Dec, 2007 Peer-reviewed
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology, 27(5), Nov 25, 2007
-
NEUROSCIENCE, 149(2) 256-262, Oct, 2007 Peer-reviewed
-
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 22(5) A26-A26, Sep, 2007
-
PSYCHOPHARMACOLOGY, 194(1) 21-32, Sep, 2007 Peer-reviewed
-
FASEB JOURNAL, 21(9) 1994-2004, Jul, 2007 Peer-reviewed
-
JOURNAL OF NEUROSCIENCE, 27(28) 7604-7615, Jul, 2007 Peer-reviewed
-
BIOLOGICAL PSYCHIATRY, 62(2) 148-157, Jul, 2007 Peer-reviewed
-
JOURNAL OF NEUROCHEMISTRY, 101(5) 1392-1399, Jun, 2007 Peer-reviewed
-
NEUROSCIENCE, 146(1) 50-59, Apr, 2007 Peer-reviewed
-
NEUROSCIENCE, 146(1) 60-68, Apr, 2007 Peer-reviewed
-
NATURE, 446(7131) 41-45, Mar, 2007 Peer-reviewed
-
LEARNING & MEMORY, 14(3) 117-125, Mar, 2007 Peer-reviewed
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103(3) 299-308, Mar, 2007 Peer-reviewed
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103(3) 329-332, Mar, 2007 Peer-reviewed
-
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 320(2) 819-827, Feb, 2007 Peer-reviewed
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 230P-230P, 2007
-
NEUROSCIENCE RESEARCH, 58 S122-S122, 2007
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 45P-45P, 2007
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 226P-226P, 2007
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 12P-12P, 2007
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 33P-33P, 2007
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 125P-125P, 2007
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 116P-116P, 2007
-
JOURNAL OF NEUROSCIENCE, 26(47) 12374-12383, Nov, 2006 Peer-reviewed
-
MOLECULAR PHARMACOLOGY, 70(5) 1720-1725, Nov, 2006 Peer-reviewed
-
NEUROREPORT, 17(13) 1453-1457, Sep, 2006 Peer-reviewed
-
BEHAVIOURAL BRAIN RESEARCH, 166(2) 296-296, Jan, 2006
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 100 205P-205P, 2006
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 100 147P-147P, 2006
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 101 90-90, 2006
-
NEUROSCIENCE RESEARCH, 55 S169-S169, 2006
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 100 88P-88P, 2006
-
BIOLOGICAL PSYCHIATRY, 59(1) 75-84, Jan, 2006 Peer-reviewed
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology, 25(6), Dec 25, 2005
-
NEUROPSYCHOPHARMACOLOGY, 30 S26-S26, Dec, 2005
-
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 102(44) 16066-16071, Nov, 2005 Peer-reviewed
-
日本医療薬学会年会講演要旨集, 15 335-335, Sep 1, 2005
Books and Other Publications
1Presentations
19Teaching Experience
16-
2025 - Present
-
2025 - Present
-
2024 - Present
-
2023 - Present
-
2023 - Present
Professional Memberships
8Research Projects
23-
科学研究費助成事業, 日本学術振興会, Apr, 2024 - Mar, 2027
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2023 - Mar, 2026
-
脳とこころの研究推進プログラム(精神・神経疾患メカニズム解明プロジェクト), AMED, 2021 - 2024
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2020 - Mar, 2023
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2020 - Mar, 2023
Industrial Property Rights
1Other
1-
統合失調症マーカー及びその利用, 尾崎紀夫, 永井拓, 吉見陽, 山田真之亮.「国立大学法人名古屋大学, 特許番号6252949, 出願番号 特願 2014-542025, 管理番号 C20130185JP#P01, 出願日2013.10.3., 特許取得2017.12.8.